Compare Stocks: RYTM, ROIV, INSM, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$116.61 -0.5%	$123.85	$82.82 ▼ $132.60	$23.63B	0.74	1.71 million shs	223,290 shs
INSM Insmed	$108.31 -0.3%	$120.12	$90.39 ▼ $212.75	$23.65B	0.83	2.89 million shs	508,091 shs
ROIV Roivant Sciences	$35.37 -0.4%	$36.57	$15.25 ▼ $42.50	$25.52B	1.1	6.40 million shs	381,524 shs
RYTM Rhythm Pharmaceuticals	$94.55 +1.2%	$105.61	$74.50 ▼ $122.20	$6.48B	2.01	753,286 shs	34,334 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	-3.47%	-5.87%	-6.30%	+0.24%	+35.11%
INSM Insmed	-4.86%	-10.66%	-10.63%	-2.70%	-26.27%
ROIV Roivant Sciences	-2.93%	-1.74%	+2.84%	+1.05%	+125.40%
RYTM Rhythm Pharmaceuticals	-1.89%	-4.98%	-10.82%	-18.18%	-6.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$116.61 -0.5%	$123.85	$82.82 ▼ $132.60	$23.63B	0.74	1.71 million shs	223,290 shs
INSM Insmed	$108.31 -0.3%	$120.12	$90.39 ▼ $212.75	$23.65B	0.83	2.89 million shs	508,091 shs
ROIV Roivant Sciences	$35.37 -0.4%	$36.57	$15.25 ▼ $42.50	$25.52B	1.1	6.40 million shs	381,524 shs
RYTM Rhythm Pharmaceuticals	$94.55 +1.2%	$105.61	$74.50 ▼ $122.20	$6.48B	2.01	753,286 shs	34,334 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	-3.47%	-5.87%	-6.30%	+0.24%	+35.11%
INSM Insmed	-4.86%	-10.66%	-10.63%	-2.70%	-26.27%
ROIV Roivant Sciences	-2.93%	-1.74%	+2.84%	+1.05%	+125.40%
RYTM Rhythm Pharmaceuticals	-1.89%	-4.98%	-10.82%	-18.18%	-6.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INCY Incyte	2.56	Moderate Buy	$126.15	8.19% Upside
INSM Insmed	3.00	Buy	$200.57	85.19% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	29.03% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.67	48.78% Upside

Current Analyst Ratings Breakdown

Latest RYTM, ROIV, INSM, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	INCY Incyte	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$116.00 ➝ $128.00
9/30/2026	INSM Insmed	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$237.00 ➝ $207.00
9/28/2026	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/28/2026	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$120.00 ➝ $123.00
9/28/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$150.00 ➝ $152.00
9/24/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/22/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$109.00
9/17/2026	RYTM Rhythm Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INCY Incyte	$5.14B	4.60	$5.94 per share	19.63	$26.32 per share	4.43
INSM Insmed	$606.42M	39.00	N/A	N/A	$3.46 per share	31.30
ROIV Roivant Sciences	$8.26M	3,093.03	N/A	N/A	$7.35 per share	4.81
RYTM Rhythm Pharmaceuticals	$189.76M	34.14	N/A	N/A	$2.08 per share	45.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INCY Incyte	$1.29B	$7.85	14.85	15.16	3.68	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	112.82	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest RYTM, ROIV, INSM, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	INSM Insmed	-$0.3911	N/A	N/A	N/A	$500.95 million	N/A
10/27/2026	Q3 2026	INCY Incyte	-$3.33	N/A	N/A	N/A	$1.47 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INCY Incyte	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INCY Incyte	N/A	4.59	4.51
INSM Insmed	0.74	3.72	3.40
ROIV Roivant Sciences	N/A	16.72	16.72
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INCY Incyte	96.97%
INSM Insmed	N/A
ROIV Roivant Sciences	64.76%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
INCY Incyte	16.20%
INSM Insmed	2.10%
ROIV Roivant Sciences	8.80%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

RYTM, ROIV, INSM, and INCY Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67 According to Brokerages

September 30 at 4:15 AM | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67

September 30 at 4:13 AM | marketbeat.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

Critical Comparison: Anika Therapeutics (NASDAQ:ANIK) and Rhythm Pharmaceuticals (NASDAQ:RYTM)

September 28, 2026 | americanbankingnews.com

Rhythm Pops on Health Canada Nod

September 23, 2026 | baystreet.ca

Rhythm Pharmaceuticals, Inc. Announces Health Canada Approval Of IMCIVREE (Setmelanotide) For Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With ...

September 23, 2026 | marketscreener.comM

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

September 23, 2026 | streetinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with ...

September 22, 2026 | markets.businessinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

September 22, 2026 | globenewswire.com

325,470 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Bank of America Corp DE

September 22, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

September 17, 2026 | marketscreener.comM

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

September 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

September 15, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners

September 14, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology Meeting

September 11, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RYTM, ROIV, INSM, and INCY Company Descriptions

Incyte NASDAQ:INCY

$116.60 -0.54 (-0.46%)

As of 10:27 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed NASDAQ:INSM

$108.30 -0.29 (-0.26%)

As of 10:27 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences NASDAQ:ROIV

$35.37 -0.13 (-0.37%)

As of 10:27 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Rhythm Pharmaceuticals NASDAQ:RYTM

$94.54 +1.14 (+1.22%)

As of 10:26 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RYTM, ROIV, INSM, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RYTM, ROIV, INSM, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RYTM, ROIV, INSM, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RYTM, ROIV, INSM, and INCY Company Descriptions

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RYTM, ROIV, INSM, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RYTM, ROIV, INSM, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RYTM, ROIV, INSM, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RYTM, ROIV, INSM, and INCY Company Descriptions

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools